UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 1224, 2016

Rock Creek Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

000-15324

52-1402131

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2040 Whitfield Avenue, Suite 300

Sarasota, Florida 34243

(Address of principal executive offices, including zip code)

844-727-0727

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 52.0704. ~~Submission~~Triggering ofEvents ~~Matters~~That toAccelerate or Increase a ~~Vote~~Direct ofFinancial ~~Security~~Obligation ~~Holders~~or an Obligation under an Off-Balance Sheet Arrangement.

On August 1224, 2016, Rock Creek Pharmaceuticals, Inc. (the “Company”) ~~held~~received ~~its annual~~an ~~meeting~~Event of ~~stockholders~~Default Redemption Notice from Hudson Bay Master Fund Ltd., ~~The~~a Note holder in the Company’s ~~previously~~October ~~filed~~2015 ~~the~~private ~~Proxy~~placement ~~Statement~~of ~~and~~$20 ~~related~~million ~~materials~~in ~~pertaining~~principal toamount ~~the~~of ~~Annual Meeting~~Senior ~~with~~Secured ~~the~~Convertible ~~SEC~~Notes (the “Notes”). OnAlso on August 24, 2016, the ~~record~~Company ~~date~~received an Event of ~~July~~Default ~~22,~~Notice ~~2016,~~from ~~there~~Tenor ~~were~~Capital ~~170~~Management,~~444,758~~ ~~shares~~on behalf of ~~Common~~Alto ~~Stock~~Opportunity ~~outstanding~~Master ~~and~~Fund, ~~entitled to~~SPC, ~~vote~~also ata ~~the~~Note ~~Annual~~holder ~~Meeting~~of the Notes.

~~Proposal~~The 1:notice ~~Election~~received from Hudson Bay stated that pursuant to Section 14(o)(4) of ~~Directors~~the Note, the Holder may withdraw all or any part of the Collateral in the Holder Master Restricted Account upon the occurrence of any event which could reasonably be expected to result in a Cash Payment Obligation. Hudson Bay withdrew $6,664,188.87 from its Holder Master Restricted Account, leaving a balance of $200,000 in the account. Further, the notice constituted an Event of Default Redemption Notice in accordance with terms of Section 5(b) of the Note. Among other things, the notice claimed the Company failed to comply with Section 14(q)(i) of the Note and therefore, an Event of Default had occurred as set forth in Section 4(a)(xvi) of the Note.

~~Three~~Hudson ~~nominees~~elected ~~for~~to redeem $3,835,972.13 of the ~~Board~~Conversion Amount outstanding under the Note at the Event of ~~Directors were~~Default ~~elected~~Redemption Price of $6,664,188.87 and to ~~serve~~apply ~~for~~the Collateral ~~one-year~~withdrawn ~~terms~~in satisfaction in full of the Cash Payment Obligation. ~~The~~After ~~tabulation~~giving effect to the redemption and based on Hudson Bay’s calculation of ~~votes~~the ~~was~~Event asof ~~follows:~~Default Redemption Price, Hudson Bay claims it retains a Note with an outstanding Principal amount equal to $6,996,8709.16.

Nominee	Votes For	Votes Withheld
Lee M. Canaan	37,956,908	4,123,314
Michael John Mullan	37,911,618	4,168,604
Robert W. Scannell	38,025,629	4,054,593

The notice from Tenor alleged an Event of Default under Section 4(a)(iv)(B) of the Note indicating that the Company would not be able to comply with conversion requests. The notice further alleged that the Company was not in compliance with financial covenants in Section 14(a) of the Note, which constituted an Event of Default. Tenor exercised its rights pursuant to Section 4(b) of the Note to require the entire outstanding principal amount and other amounts outstanding under the Note to accelerate and to become due and payable. Tenor has demanded payment of $7,322,815.24, which they claim are all amounts outstanding and payable under the Note. As partial payment, Tenor has withdrawn the entire balance of $3,517,255.56 from the Tenor Master Restricted Account and has demanded the balance remaining of $3,805,559.68 to be paid in cash no later than August 31, 2016.

~~Proposal~~Prior 2:to Areceiving ~~proposal~~the default notices, the Company had, at the request of the lenders, sought and obtained approval from its stockholders to ~~approve~~do ana reverse ~~amendment~~split. (Also, as previously disclosed, the Company has been seeking additional funding from other sources. The Company was in discussions with the ~~event~~Note itholders isregarding ~~deemed~~these bymatters when they issued the ~~Company’s~~notices. ~~Board~~Through the date of ~~Directors~~the tonotice, bethe Company ~~advisable)~~had toreceived $5,275,000 in cash proceeds from the Note and the total amount being demanded by the Note holders, after sweeping the cash from the Restricted Accounts is $10,802,429.84. The Company’s ~~Tenth~~has ~~Amended~~neither agreed to nor denied the ~~and~~allegations ~~Restated~~in ~~Certificate~~the notice or the calculations of ~~Incorporation,~~the asalleged ~~amended,~~balances due to ~~effect~~the aNote ~~reverse~~holders. ~~stock~~As ~~split~~of the date of the notices, the Company’s ~~issued~~had approximately $35,000 in its unrestricted cash accounts. The Company is actively exploring all options for treatment of its debt and ~~outstanding~~funding its operating needs, including, but not limited to, initiation of proceedings under laws ~~common~~relating ~~stock~~to bankruptcy or insolvency.

The Company’s proposal to approve an amendment (in the event it is deemed by the Company’s Board of Directors to be advisable) to the Company’s Tenth Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s issued and outstanding common stock at a ratio within the range of one-for-fifty (1:50) to one-for-two hundred (1:200), as determined by the Board of Directors, was approved as set forth below:SIGNATURES

For	Against	Abstain
95,790,971	42,532,084	1,919,301

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Proposal 3: Approval of the Company’s 2016 Omnibus Incentive Plan

	ROCK CREEK PHARMACEUTICALS, INC.

Date: August 29, 2016

	By:	/s/ William L. McMahon
	Name:	William L. McMahon
	Title:	Chief Financial Officer

The Company’s proposal to approve the Company’s 2016 Omnibus Incentive Plan was approved as set forth below:

For	Against	Abstain	Broker Non-Votes
30,275,080	10,074,178	1,730,964	96,162,134

Proposal 4: Ratification of the Appointment of Independent Auditor

The appointment of Cherry Bekaert LLP as the Company’s independent auditor to audit the Company’s 2016 financial statements was ratified as set forth below:

For	Against	Abstain
134,507,671	3,078,932	2,655,753

Proposal 5: Advisory Vote on Executive Compensation

An advisory resolution on the compensation of the Company’s named executive officers was ratified as set forth below:

For	Against	Abstain	Broker Non-Votes
45,528,252	8,943,611	2,894,316	96,100,877

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ROCK CREEK PHARMACEUTICALS, INC.
Date: August 17, 2016
	By:	/s/ William L. McMahon
	Name:	William L. McMahon
	Title:	Chief Financial Officer

Filing Compare · ROCK CREEK PHARMACEUTICALS, INC.